menu
    • menu
    [{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Zinc Acetate Dihydrate","moa":"Intestinal cell metallothionein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zinc Acetate Dihydrate","moa":"Intestinal cell metallothionein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Zinc Acetate Dihydrate

    Menu

    Zinc Acetate Dihydrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eton Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Eton Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zinc Acetate Dihydrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

                            Details : Galzin (zinc acetate) is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent.

                            Product Name : Galzin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : Zinc Acetate Dihydrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Teva Pharmaceutical Industries

                            Israel arrow
                            SupplySide West
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zinc Acetate Dihydrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Advances its Commitment to Rare Disease with Acquisition of Galzin

                            Details : Through the acquisition, Eton will add additional commercial and strategic rare disease products such as Galzin (zinc acetate), which is an FDA-approved product for the treatment of Wilson's Disease.

                            Product Name : Galzin

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 03, 2025

                            Lead Product(s) : Zinc Acetate Dihydrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth